Literature DB >> 19581636

Positron emission tomography in staging early lung cancer: a randomized trial.

Donna E Maziak1, Gail E Darling, Richard I Inculet, Karen Y Gulenchyn, Albert A Driedger, Yee C Ung, John D Miller, Chu-Shu Gu, Kathryn J Cline, William K Evans, Mark N Levine.   

Abstract

BACKGROUND: Among patients with early-stage non-small cell lung cancer (NSCLC), preoperative imaging tests are important in defining surgical candidates.
OBJECTIVE: To assess whether whole-body positron emission tomography and computed tomography (PET-CT) plus cranial imaging correctly upstages cancer in more patients with NSCLC than does conventional staging plus cranial imaging.
DESIGN: Randomized clinical trial with recruitment from June 2004 to August 2007. The centralized, computer-generated, variable block size randomization scheme was stratified by treatment center and cancer stage. Participants, health care providers, and outcome assessors were not blinded to imaging modality assignment.
SETTING: 8 hospitals and 5 PET-CT centers in academic institutions. PATIENTS: Eligible patients were older than 18 years; had histologic or cytologic proof of stage I, II, or IIIA NSCLC on the basis of chest radiography and thoracic CT; and had a tumor considered to be resectable. INTERVENTION: PET-CT or conventional staging (abdominal CT and bone scan). All patients also had cranial imaging using CT or magnetic resonance imaging. MEASUREMENTS: The primary outcome was correct upstaging, thereby avoiding stage-inappropriate surgery. Secondary outcomes were incorrect upstaging and incorrect understaging.
RESULTS: 170 patients were assigned to PET-CT and 167 to conventional staging. Eight patients (3 who had PET-CT and 5 who had conventional staging) did not have planned surgery. Disease was correctly upstaged in 23 of 167 PET-CT recipients and 11 of 162 conventional staging recipients (13.8% vs. 6.8%; difference, 7.0 percentage points [95% CI, 0.3 to 13.7 percentage points]), thereby sparing these patients from surgery. Disease was incorrectly upstaged in 8 PET-CT recipients and 1 conventional staging recipient (4.8% vs. 0.6%; difference, 4.2 percentage points [CI, 0.5 to 8.6 percentage points]), and it was incorrectly understaged in 25 and 48 patients, respectively (14.9% vs. 29.6%; difference, 14.7 percentage points [CI, 5.7 to 23.4 percentage points]). At 3 years, 52 patients who had PET-CT and 57 patients who had conventional staging had died. LIMITATION: The relatively small sample and the fact that some patients did not have planned surgery limited the ability to determine precise differences in clinical outcomes that were attributable to testing strategies.
CONCLUSION: Preoperative staging with PET-CT and cranial imaging identifies more patients with mediastinal and extrathoracic disease than conventional staging, thereby sparing more patients from stage-inappropriate surgery, but the strategy also incorrectly upstaged disease in more patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581636     DOI: 10.7326/0003-4819-151-4-200908180-00132

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  42 in total

Review 1.  Colonic metastasis from primary lung adenocarcinoma: case report and review of the literature.

Authors:  Xing-Yang Xue; Ming Zhou; Wen-Fan Fu; You-Guang Pan; Jian Zhao
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  What is quality, and can we define it in lung cancer?-the case for quality improvement.

Authors:  Farhood Farjah; Frank C Detterbeck
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  Imaging: PET-CT imaging in non-small-cell lung cancer.

Authors:  Mark Levine; Jim Julian
Journal:  Nat Rev Clin Oncol       Date:  2009-11       Impact factor: 66.675

Review 4.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

5.  Lung cancer staging: the value of PET depends on the clinical setting.

Authors:  Frank C Detterbeck; Santiago Figueroa Almanzar
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

6.  Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study.

Authors:  Michael K Gould; Ellen M Schultz; Todd H Wagner; Xiangyan Xu; Sharfun J Ghaus; Robert B Wallace; Dawn Provenzale; David H Au
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

7.  Advanced imaging and hospice use in end-of-life cancer care.

Authors:  Michaela A Dinan; Lesley H Curtis; Soko Setoguchi; Winson Y Cheung
Journal:  Support Care Cancer       Date:  2018-05-04       Impact factor: 3.603

8.  Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review.

Authors:  M Smoragiewicz; J Laskin; D Wilson; K Ramsden; J Yee; S Lam; T Shaipanich; Y Zhai; C Ho
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

9.  The clinical significance of subcarinal lymph node dissection in the radical resection of oesophageal cancer.

Authors:  Haibo Ma; Yin Li; Zhidan Ding; Xianben Liu; Jinliang Xu; Jianjun Qin
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-03-08

10.  Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer.

Authors:  Farhood Farjah; David K Madtes; Douglas E Wood; David R Flum; Megan E Zadworny; Rachel Waworuntu; Billanna Hwang; Michael S Mulligan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-06       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.